Product Reports Resources Pricing Login Book a demo
Investor profile

Cormorant Asset Management

Venture Capital · Founded 2013 · Boston, United States

Its services to pooled investment vehicles

164 portfolio companies Venture Capital · $19B invested · 249 investments · Investor rank #132 · Last investment 7/2026
Portfolio companies 164 ↑ 33% 5y
Decacorns 4
Thoroughbreds 20 ↑ 6% 5y
01 · Biggest holdings

Cormorant Asset Management’s biggest current holdings.

The most valuable companies Cormorant Asset Management still holds — unicorns and thoroughbreds it has backed, ordered by Dealroom’s latest valuation. Companies that have been acquired or gone public are in Exits instead.

#CompanyEst. stakeValuationEst. value
  1. 1 Tessera TherapeuticsUnicorn · Health · USA $1.5B
  2. 2 Umoja BiopharmaUnicorn · Health · USA $1.1B

Estimated value = Cormorant Asset Management’s disclosed ownership % × Dealroom’s latest company valuation; direct named stakes only, exited positions excluded. Figures are indicative, not reported marks. See the underlying cap tables on Dealroom →

02 · Exits

Cormorant Asset Management’s biggest exits.

Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from Cormorant Asset Management’s transaction record.

$2.0B IPO · 2019
Entered Series B+Now $18BHealth
$2.0B IPO · 2018
Entered Series B+Now $18BHealth
IPO · 2015
Entered Series ANow $13BHealth
IPO · 2020
Entered Series B+Now $12BHealth
$698M IPO · 2020
Entered Series B+Now $9.3BHealth
$130M IPO · 2016
Now $8.1BHealth
$372M IPO · 2018
Entered Series B+Now $7.2BHealth
$345M IPO · 2021
Entered Series ANow $6.2BHealth
$1.9B IPO · 2021
Entered Series ANow $6.1BHealth
$691M IPO · 2017
Entered Series B+Now $5.3BHealth
Parabilis Medicines
$2.4B IPO · 2026
Entered Series B+Now $4.8BHealth
$4.7B IPO · 2021
Entered Series B+Now $1.6BHealth
03 · Portfolio analysis

Where Cormorant Asset Management’s portfolio is concentrated.

Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 164 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.

By countryCount
  1. USA157
  2. China8
  3. Denmark2
  4. France2
  5. Ireland2
  6. Switzerland2
  7. UK2
  8. Belgium1
  9. Canada1
  10. Germany1
  11. Netherlands1
By sectorCount
  1. Health176
  2. Food3
  3. Chemicals1
  4. Jobs Recruitment1
  5. Media1
  6. Robotics1
  7. Transportation1
By stage enteredCount
  1. Series B+114
  2. Series A40
  3. Seed2
By growth stageCount
  1. Late Growth148
  2. Breakout Stage28
  3. Early Growth3
04 · Portfolio market map

Inside Cormorant Asset Management’s portfolio.

The 60 highest-funded portfolio companies, of 164 tracked.

Freenome
Health · Unicorn
$1.3B
Zai Lab
Health · Unicorn
$2.1B
Parabilis Medicines
Health · Unicorn
$4.8B
BridgeBio
Health · Decacorn
$18B
Innovent Biologics
Health · Decacorn
$18B
Tessera Therapeutics
Health · Unicorn
$1.5B
Avidity Biosciences
Health · Decacorn
$12B
Alumis
Health · Unicorn
$3.0B
Solid Biosciences
Health
$541M
Neurogene
Health
$429M
Olema Oncology
Health
$550M
Galecto | Damora Therapeutics
Health · Unicorn
$1.9B
RayzeBio
Health · Unicorn
$3.7B
Constellation Pharmaceuticals
Health · Unicorn
$1.7B
Korro Bio
Health
$122M
Greenlight Biosciences
Health
$46M
Ventus Therapeutics
Health
$280M
Verve Therapeutics
Health
$566M
Umoja Biopharma
Health · Unicorn
$1.1B
Everest Medicines
Health
$898M
Terremoto Biosciences
Health
$875M
Tyra Biosciences
Health · Unicorn
$1.2B
Affinivax
Health · Unicorn
$2.1B
Tango Therapeutics
Health · Unicorn
$4.1B
Ambrx
Health · Unicorn
$1.6B
Aspen Neuroscience
Health
$738M
Erasca
Health · Unicorn
$6.2B
Pyxis Oncology
Health
$214M
Crystalys Therapeutics
Health · Unicorn
$1.0B
AltruBio
Health
$900M
Adarx Pharmaceuticals
Health
$800M
Agomab
Health
$425M
Viela Bio
Health · Unicorn
$3.0B
Neurona Therapeutics
Health
$600M
Star Therapeutics
Health
$500M
Talaris Therapeutics
Health
Gelesis
Health
$54M
Orchard Therapeutics
Health
$303M
Harpoon Therapeutics
Health
$475M
GondolaBio
Health · Unicorn
$1.2B
BioAge Labs
Health
$680M
Adlai Nortye
Health
$874M
Eliem Therapeutics
Health
$494M
Triveni Bio
Health
$575M
Latigo Biotherapeutics
Health
$600M
JenaValve Technology
Health
$400M
Electra Therapeutics
Health
$732M
Fore Biotherapeutics
Health
$270M
NiKang Therapeutics
Health
$382M
Ventyx Biosciences
Health
$822M
Chroma Medicine
Health
$540M
Elpiscience Biopharmaceuticals
Health
$420M
Ensoma
Health
$425M
Attovia
Health
$525M
Rapport Therapeutics
Health · Unicorn
$1.8B
Centessa Pharmaceuticals
Health · Unicorn
$6.1B
Twist Bioscience
Health · Unicorn
$7.2B
Supira Medical
Health
$480M
Moma Therapeutics
Health
$600M
Spyre Therapeutics | Aeglea BioTherapeutics
Health · Unicorn
$8.1B
05 · Portfolio founders

Where Cormorant Asset Management’s portfolio founders come from.

150 founders across the 100 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.

LocationCount
  1. United States117
  2. United Kingdom7
  3. China5
  4. Belgium4
  5. Switzerland4
  6. Denmark3
  7. Netherlands3
  8. Cuba1
  9. France1
  10. Israel1
UniversityCount
  1. Massachusetts Institute of Technology18
  2. Harvard University7
  3. Stanford University7
  4. University of California, Berkeley7
  5. University of California, San Diego6
  6. Harvard Medical School5
  7. The Ohio State University4
  8. University College London4
  9. MIT Sloan School of Management3
  10. Stanford University School of Medicine3
Previous companyCount
  1. Harvard Medical School5
  2. Novartis5
  3. Estring4
  4. Genentech4
  5. McKinsey & Company4
  6. Pfizer4
  7. Broad Institute3
  8. Dana-Farber Cancer Institute3
  9. Lucentis3
  10. Massachusetts General Hospital3